Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Blink Charging

Riot Blockchain

Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.

4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025

Inovio Pharmaceuticals

Planet Fitness

Our Fool roundtable picks three COVID stocks they think are dangerous at these prices.

3 Scary COVID Stocks to Avoid

Novavax's Covid-19 vaccine has strong potential outside the U.S and will generate revenue. This dip is a chance to buy NVAX stock.

Buy Novavax In Its Post-Earnings Dip

With the worsening Covid-19 crisis, NVAX stock offers relevance in the international market but you should remain vigilant. The post The Delta Variant Gives Novavax an Outside Chance of Upside appeared first on InvestorPlace.

The Delta Variant Gives Novavax an Outside Chance of Upside

BioNTech SE

Moderna

The vaccine stock rally could be near its end.

Why Moderna, Novavax, and BioNTech Stocks Dropped Today

CureVac B.V

Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering. The post Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today appeared first on InvestorPlace.

Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today

Find out what's sending stocks in a high-growth area down so sharply.

These Nasdaq Vaccine Stocks Are Feeling the Pain Monday

Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What Happened: Novavax announced Monday it has appointed biopharma industry veteran Jim Kelly as executive vice president, CFO and treasurer.

Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization

GAITHERSBURG, Md., Aug. 16, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, and Nasir Egal, Ph.D.

Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance

Maryland-based Novavax made immense progress of late, which positions NVAX stock as one of the most promising in the biotech space. The post Novavax Has a Good Outlook and Is Positioned For Growth appeared first on InvestorPlace.

Novavax Has a Good Outlook and Is Positioned For Growth

Novavax has manufacturing problems, but its vaccine candidate seems to work well against COVID-19. The post Novavax: Bronze Medal May Be Good Enough in COVID Race appeared first on InvestorPlace.

Novavax: Bronze Medal May Be Good Enough in COVID Race

Dynavax Technologies

Sorrento Therapeutics Inc

There were different reasons behind each of these COVID-19 vaccine stocks' big gains.

Why Dynavax, Novavax, and Sorrento Soared This Week

NVAX stock seems attractive for accumulation in the recent correction. Vaccine focus on low-income countries is likely to deliver growth.

Novavax Stock Is a Buy Even After the Company's Post-Dip Bounce

Pinterest

Pubmatic

Teladoc

Short-term pain in these innovators means long-term opportunity for investors.

Like Discounts? These 5 Game-Changing Stocks Are 35% (or More) Below Their 52-Week Highs

Good news keeps rolling in for Novavax. However, for NVAX stock to return to $300, it needs a little help from Wall Street analysts.

If You Can Buy Novavax Stock at Around $200, It's a Great Long Term Bet

NVAX stock fell behind other vaccine plays early in 2021, but it might not stay behind, There's lots of evidence to suggest it could move soon The post Novavax Is Looking More Like a Bet Worth Taking appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar

Novavax Is Looking More Like a Bet Worth Taking

Novavax, Inc (NASDAQ: NVAX) shares closed 12.24% higher in the regular session on Monday. What Happened: The biotechnology company working on a COVID-19 vaccine saw its shares move 0.74% higher in the after-hours trading.

What's Up With Novavax Stock?

Coronavirus fears sparked a rally in the shares of the major vaccine makers.

Why Moderna, BioNTech, and Novavax Stock Soared Today

Novavax reported a delay in filing for its EUA with the US FDA, leading to a post-earnings sell-off of close to 20%. We present our thesis on why we think that the market's myopia has once again provided investors a great opportunity to add Novavax to their portfolio.

Novavax Stock: A Great Opportunity To Buy On Post-Earnings Weakness

eBay

SPDR S&P Biotech ETF

Even at all time high indices there are stocks to buy. Today we find three swing trade opportunities while the bulls are in charge.

3 Stocks to Buy for the Second Half of 2021

Activision Blizzard

Boeing

General Motors

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Facebook among others.

Facebook Ranked Among Today's Trending Stocks

NVAX stock has a high valuation, while the company has had manufacturing challenges. Consequently, the risk-reward ratio is negative.

Novavax Stock Has a Lot More Going for It Than You Might Think

The company's executives have repeatedly overpromised and underdelivered.

Is Novavax Stock Still a Buy With Its Management's Credibility Crumbling?

Novavax: The Race Is Far From Over Yet

In my opinion, Novavax executives turned a sure-fire positive Earnings Call into a PR disaster and a bear's picnic. Five massive forward steps were announced but negated due to teething problems not being professionally addressed.

News for Novavax Stock (NVAX)